## The YODA Project Research Proposal Due Diligence Assessment

Part 1: General Information		
YODA Project (Protocol) ID:	2019-4090	
Date:	6 April 2020	
Product Name:	Abiraterone acetate	
Therapeutic Area:	Oncology	
Product Class:	CYP17 inhibitor	
Condition(s) Studied:	Prostate Cancer	
Protocol Number(s) and Title(s):	NCT00638690 - COU-AA-301 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy  NCT00887198 - COU-AA-302 - A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer	
Part 2: Data Availability		
Data Holder has authority to pr	•	Yes
Data Holder has authority to provide clinical trial data or development partner has agreed to share clinical trial data.		163
Comments:		
Data Holder has sharable electronic clinical trial data or data can be converted		Yes
to electronic format.		
Comments:     De-identification and redaction of clinical trial data in accordance with current   Yes		
HIPAA and EU criteria allows protection of participant privacy and confidentiality.		
Comments:  The product and relevant indication studied has either been approved by  Yes		
regulators in the US and EU, or terminated from development.		162
Comments:		
Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).		
Comments:		
Part 3: Data Availability Summary		
Based on the responses to the above Data Availability questions, the		Yes
requested clinical trial data are available for a data sharing request.		
Part 4: Proposal Review		
Question:		Response:
Summary-level CSR data is appropriate for the proposed analysis.		No
Participant-level data is appropriate for the proposed analysis.  A similar analysis is underway or completed/pending disclosure by Janssen.		Yes No
Comments:		